Connect Biopharma Holdings Ltd (CNTB) ADR EACH REPR 1 ORD SHS UNSPON
Sell:$0.80Buy:$0.84
$0.01
(0.62%)
- This stock can be held in a
Stocks and Shares ISA
SIPP$0.01
(0.62%)$0.01
(0.62%)Company Information
About this company
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Key people
Key facts
- EPICCNTB
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS2075231017
- Market cap$45.47m
- Employees62
- Shares in issue0.00
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.